Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
Purpose: Results from the LAUNCH trial suggest transarterial chemoembolization (TACE) in combination with lenvatinib is significantly more effective than lenvatinib as a first-line treatment option for advanced hepatocellular carcinoma (HCC). However, the cost of TACE is substantial. This study comp...
Saved in:
Main Authors: | Ying He (Author), Wangchun Lin (Author), Zhongjie Cai (Author), Yufan Huang (Author), Maojin You (Author), Meisheng Lei (Author), Ruijia Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020) -
Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan
by: Hiroki Higashihara, et al.
Published: (2021) -
Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma
by: Zizhuo Wang, et al.
Published: (2024) -
Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
by: Qing-Yun Xie, et al.
Published: (2022) -
Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
by: Guoliang Shao, et al.
Published: (2022)